Related Experiment Video
Updated: Sep 11, 2025

An In Vitro Model of a Parallel-Plate Perfusion System to Study Bacterial Adherence to Graft Tissues
Published on: January 7, 2019
Drug treatment analysis of infective endocarditis in children-a retrospective, single-centre study
Insights
This study on pediatric infective endocarditis found Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus (MRSA), were common. Treatment involved specific antibiotics, but drug monitoring was infrequent.
Area of Science:
- Pediatric Infectious Diseases
- Cardiology
- Antimicrobial Resistance
Background:
- Infective endocarditis (IE) in children is a serious condition requiring prompt diagnosis and effective treatment.
- Understanding causative pathogens and their antimicrobial susceptibility is crucial for guiding therapy.
Purpose of the Study:
- To retrospectively analyze pediatric infective endocarditis cases.
- To characterize causative pathogens, antimicrobial susceptibility, and treatment outcomes.
- To inform clinical decision-making for pediatric IE management.
Main Methods:
- Retrospective analysis of medical records from 2016-2023.
- Identification and characterization of bacterial isolates.
- Review of clinical data, treatment plans, and pharmaceutical monitoring.
Main Results:
- Twelve pediatric IE cases identified; predominantly Gram-positive cocci.
- Staphylococcus aureus, all methicillin-resistant Staphylococcus aureus (MRSA), was the most frequent pathogen (n=13).
- Linezolid and vancomycin were primary antimicrobials; therapeutic drug monitoring was low (25% for vancomycin).
Conclusions:
- Gram-positive cocci, particularly MRSA, dominate pediatric IE etiology.
- Significant variation in drug resistance observed among streptococci species.
- Low rates of therapeutic drug monitoring highlight a potential area for improvement in patient care.
Objective:
A retrospective analysis of paediatric infective endocarditis characterised causative pathogens, antimicrobial susceptibility patterns, and treatment outcomes to guide clinical decision-making.
Methods:
The data of patients who received infective endocarditis between 2016 and 2023 were retrospectively collected from the medical records database. The clinical characteristics, treatment plans, and pharmaceutical monitoring characteristics were analysed and summarised.
Results:
A total of 12 paediatric infective endocarditis cases were identified. Bacterial isolates included 27 Gram-positive and 1 Gram-negative strains. The most common pathogen was Staphylococcus aureus (n = 13), all methicillin-resistant Staphylococcus aureus (MRSA), followed by Abiotrophia defectiva (n = 6), Streptococcus mitis (n = 5), Streptococcus sanguinis (n = 2), Bacillus cereus (n = 1), and Klebsiella oxytoca (n = 1). Antimicrobial therapy primarily involved linezolid, vancomycin, and cephalosporin/enzyme inhibitor combinations. Cardiac glycosides were used in 10 cases, and all patients received phosphocreatine to support myocardial energy metabolism. Therapeutic drug monitoring for vancomycin was performed in 25% of cases, while no therapeutic drug monitoring was conducted for meropenem or linezolid.
Conclusion:
All the causative organisms were predominantly Gram-positive cocci, with MRSA accounting for the largest proportion; different streptococci varied considerably in terms of drug resistance. The antimicrobial drugs used were predominantly linezolid and glycopeptides. The rate of blood concentration monitoring was low.
More Related Videos
Related Concept Videos
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Endocarditis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Myocarditis III: Medical Management

